Mon. 17 Jun 2024, 3:38pm ET
Benzinga
Biotech, News, General
- SEC Filing
On June 17, 2024, the Board of Directors of Scilex Holding Company (the "Company") approved a resolution to authorize management to explore ways in which to maximize the value of Semnur Pharmaceuticals, Inc. ("Semnur"), the Company's wholly owned subsidiary, and SP-102 (SEMDEXA™), the product candidate held by Semnur, for the Company and its stockholders, including by way of conducting a spin-off, merger, dividend, reclassification or other similar transaction.